Method for generating aptamers with improved off-rates

Patent metadata

Field	Value
Publication number	US-9382533-B2
Application number	US-201514606134-A
Country	US
Kind code	B2
Filing date	Jan 27, 2015
Priority date	Jan 16, 2007
Publication date	Jul 5, 2016
Grant date	Jul 5, 2016

Abstract

The present disclosure describes the identification and use of aptamers and photoaptamers having slower dissociation rate constants than those obtained using previously described methods. Specifically, the present disclosure describes methods for the identification and use of aptamers to one or more targets within a histological or cytological sample, which have slow rates of dissociation. The aptamers may be used to assess localization, relative density, and presence or absence of one or more targets in cytological and histological samples. Targets may be selected that are specific and diagnostic of a given disease state for which the sample was collected. The aptamers may also be used to introduce target specific signal moieties. In addition to target identification, the aptamers may be used to amplify signal generation through a variety of methods.

First claim

The invention claimed is:

1. A method for identifying or producing an aptamer to a target in a tissue or cell sample, the method comprising:
a) contacting a candidate mixture of nucleic acids with the tissue or cell sample, wherein at least one nucleic acid of the candidate mixture comprises at least one C-5 modified pyrimidine, and wherein nucleic acids having affinity to the target bind the target and form nucleic acid-target complexes;
b) partitioning nucleic acid-target complexes from free nucleic acids in the candidate mixture;
c) identifying nucleic acids that bind to the target in the tissue or cell sample, thereby identifying or producing an aptamer to a target in a tissue or cell sample; and
wherein, the at least one C-5 modified pyrimidine improves the off-rate of the nucleic acid compared to the nucleic acid without the at least one C-5 modified pyrimidine.

2. The method of claim 1 further comprising exposing the candidate mixture to a slow off-rate enrichment process, wherein said slow off-rate enrichment process is selected from incubation of a candidate mixture with a competitor molecule, dilution of a candidate mixture, or dilution of a candidate mixture in the presence of a competitor molecule.

3. The method of claim 1 , prior to step (c), further comprising amplifying nucleic acids to yield a mixture of nucleic acids enriched in nucleic acid sequences that are capable of binding to the target molecule.

4. The method of claim 1 , wherein the aptamer has a rate of dissociation (t½) from the target of from about 15 minutes and about 240 minutes.

5. The method of claim 4 , wherein the aptamer has a rate of dissociation (t½) from the target selected from the group consisting of a time ≧ about 15 minutes, ≧ about 30 minutes, ≧ about 60 minutes, ≧ about 90 minutes, ≧ about 120 minutes, ≧ about 150 minutes, ≧ about 180 minutes, ≧ about 210 minutes and ≧ about 240 minutes.

6. The method of claim 1 , wherein the aptamer comprises a detectable moiety.

7. The method of claim 6 , wherein the detectable moiety is selected from the group consisting of a dye, a quantum dot, a radiolabel, a electrochemical functional group, an enzyme, an enzyme substrate, a ligand and a receptor.

8. The method of claim 1 , wherein the aptamer is a single-stranded nucleic acid or a double-stranded nucleic acid.

9. The method of claim 1 , wherein the aptamer comprises DNA, RNA, or both DNA and RNA.

10. The method of claim 1 , wherein the aptamer comprises at least additional one chemical modification selected from the group consisting of a 2′-position sugar modification, a 2′-amino (2′-NH2), a 2′-fluoro (2′-F), a 2′-O-methyl (2′-OMe) a modification at a cytosine exocyclic amine, a substitution of 5-bromouracil, a substitution of 5-bromodeoxyuridine, a substitution of 5-bromodeoxycytidine, a backbone modification, methylation, a 3′cap, and a 5′cap.

11. The method of claim 1 , wherein said C-5 modified pyrimidine is independently selected from the group listed in FIG. 14 .

12. The method of claim 11 , wherein said C-5 modified pyrimidine is independently selected from the group consisting of 5-(N-benzylcarboxyamide)-2′-deoxyuridine, 5-(N-isobutylcarboxyamide)-2′-deoxyuridine, 5-(N-tryptaminocarboxyamide)-2′-deoxyuridine, 5-(N-naphthylmethylcarboxamide)-2′-deoxyuridine, 5-[N-(1-naphthyl-2-ethyl)carboxamide]-2′-deoxyuridine, 5-[N-(2-naphthylmethyl)carboxamide]-2′-deoxyuridine, 5-[N-(2-naphthyl-2-ethyl)carboxamide]-2′-deoxyuridine, 5-[N-(phenyl-3-propyl)carboxamide]-2′-deoxyuridine, 5-[N-(1-morpholino-2-ethyl)carboxamide]-2′-deoxyuridine, 5-[N-(3,4methylenedioxybenzyl)carboxamide]-2′deoxyuridine, 5-[N-((R)-2-tetrahydrofurylmethyl)carboxamide]-2′-deoxyuridine, 5-[N-((S)-2-tetrahydrofurylmethyl)carboxamide]-2′-deoxyuridine or 5-(N-[1-(2,3-dihydroxypropyl)]carboxyamide)-2′-deoxyuridine.

13. The method of claim 1 , wherein the target is selected from a protein, a peptide, a receptor, an antibody, a drug, a dye, a nutrient and a growth factor.

14. The method of claim 1 , wherein the target is selected from the group listed in FIG. 8 .

15. The method of claim 14 , wherein the target is selected from the group consisting of prostate specific antigen, CMBK, CEA, CA125, HPV16, HPV18, YKL-40, VEGF, ErbB-1 and HER2.

16. The method of claim 1 , wherein the aptamer is capable of forming a covalent bond with the target.

17. The method of claim 1 , wherein the tissue sample is selected from the group consisting of epithelium tissue, connective tissue, cartilage tissue, bone tissue, muscle tissue, nerve tissue, blood vessel tissue, heart tissue, lymphatic system tissue, respiratory tract tissue, urinary tract tissue, endocrine system tissue, tumor tissue and reproductive system tissue.

18. The method of claim 1 , wherein said cell sample is selected from the group consisting of abdominal and pelvic washings, body cavity fluids (pleural, peritoneal), urine, gastric/esophageal washings, fine needle aspirates (FNA), breast fluid, CSF, cyst fluid, synovial fluid, and bronchial washings.

19. The method of claim 1 , wherein said cell sample is cultured from epithelium tissue, connective tissue, cartilage tissue, bone tissue, muscle tissue, nerve tissue, blood vessel tissue, heart tissue, lymphatic system tissue, respiratory tract tissue, urinary tract tissue, endocrine system tissue, tumor tissue, and reproductive system tissue.

Assignees

• Somalogic Inc

Inventors

• Zichi Dominic
• Wilcox Sheri K
• Bock Chris
• Schneider Daniel J
• Eaton Bruce
• Gold Larry
• Jarvis Thale C
• Carter Jeffrey D

Classifications

• C12N15/1048 Primary

  SELEX · CPC title

• C12N15/115

  Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith {; Nucleic acids binding to non-nucleic acids, e.g. aptamers} · CPC title

• C12N2310/16

  Aptamers · CPC title

• G01N33/5308

  for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites · CPC title

• C12Q1/6811

  Selection methods for production or design of target specific oligonucleotides or binding molecules · CPC title